<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547244</url>
  </required_header>
  <id_info>
    <org_study_id>08.09.20</org_study_id>
    <nct_id>NCT04547244</nct_id>
  </id_info>
  <brief_title>CRTd Responders Optimization</brief_title>
  <official_title>Optimization of Cardiac Resynchronization Therapy and Its Effects in Patients With Type 2 Diabetes Mellitus: Automatic Optimization vs. Echocardiographic Guided Optimization.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campania &quot;Luigi Vanvitelli&quot;</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Suboptimal optimization of atrio-ventricular (AV) and inter-ventricular (VV) timings could&#xD;
      affect the clinical response of CRTd in T2DM patients. Thus, authors hypothesize that&#xD;
      automatic sensor guided CRTd optimization could ameliorate clinical outcomes in patients with&#xD;
      T2DM. However, authors will evaluate the effects of cardiac resynchronization therapy (CRTd)&#xD;
      in patients with type 2 diabetes mellitus (T2DM) optimized via automatic vs.&#xD;
      echocardiographic guided approach.Authors will conduct a prospective, multicenter study to&#xD;
      recruit, from October 2016 to June 2019, patients with T2DM and heart failure (HF) candidate&#xD;
      to receive a CRTd. After CRTd the patients will be optimized via automatic vs.&#xD;
      echocardiographic guided approach.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CRTd responders rate</measure>
    <time_frame>12 months</time_frame>
    <description>The authors will evaluate the CRTd responders rate in terms of patients that will experience the reduction of NYHA class, improvement of HF symptoms, and improvement of left ventricle ejection fraction.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Heart Failure</condition>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <condition>Cardiac Death</condition>
  <arm_group>
    <arm_group_label>T2DM patients with CRTd with automatic optimization</arm_group_label>
    <description>In this cohort the T2DM patients with CRTd will receive at follow-up an automatic optimization of CRTd.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM patients with CRTd with echocardiographic optimization</arm_group_label>
    <description>In this cohort the T2DM patients with CRTd will receive at follow-up an echocardiography guided optimization of CRTd.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>echocardiographic optimization of CRTd</intervention_name>
    <description>the patients after the implant of CRTd and during the follow-up will receive an echocardiography to optimize the atrio-ventricular and inter-ventricular delay, and to improve the effects of CRTd.</description>
    <arm_group_label>T2DM patients with CRTd with echocardiographic optimization</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged more than 18 and less than 75 affected by chronic heart failure in NYHA class&#xD;
        II/III with reduced cardiac pump and indication to receive a CRTd.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  heart failure with reduced cardiac pump, NYHA class II/III, indication to receive a&#xD;
             CRTd.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  NYHA class IV, previous CRTD implantation, neoplastic disease, inflammatory chronic&#xD;
             disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Celestino Sardu</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 7, 2020</study_first_submitted>
  <study_first_submitted_qc>September 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</investigator_affiliation>
    <investigator_full_name>Celestino Sardu</investigator_full_name>
    <investigator_title>researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

